Vertex Pharmaceuticals 대차 대조표 상태
재무 상태 기준 확인 6/6
Vertex Pharmaceuticals 의 총 주주 지분은 $15.6B 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $22.2B 및 $6.6B 입니다. Vertex Pharmaceuticals 의 EBIT는 $4.2B 이며 이자보상배율은 -6.9 입니다. $6.5B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
0%
부채 비율
US$0
부채
| 이자 보상 비율 | -6.9x |
| 현금 | US$6.52b |
| 주식 | US$15.63b |
| 총 부채 | US$6.61b |
| 총 자산 | US$22.24b |
최근 재무 상태 업데이트
업데이트 없음
Recent updates
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Nov 05Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Oct 18Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Oct 10Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Sep 15Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03재무 상태 분석
단기부채: VRTX 의 단기 자산 ( $9.8B )이 단기 부채( $4.0B ).
장기 부채: VRTX 의 단기 자산( $9.8B )이 장기 부채( $2.6B ).
부채 대 자본 내역 및 분석
부채 수준: VRTX 부채가 없습니다.
부채 감소: VRTX 5년 전에 부채가 없었습니다.
부채 범위: VRTX 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.
이자 보장: VRTX 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.